We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33. Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33.
Preliminary data suggests improved relapse-free survival compared to published groups of acute myeloid leukemia (AML) patients at high risk of relapse post-transplantTrem-cel + Mylotarg continue...
CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and...
Company to present trem-cel + Mylotarg clinical data update at American Society of Hematology (ASH) 2024 annual meetingHan Choi, M.D., LL.M, seasoned healthcare institutional investor, appointed...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.13409 | -13.3250521713 | 1.0063 | 1.03 | 0.8301 | 328013 | 0.95660196 | CS |
4 | 0.09481 | 12.1957808078 | 0.7774 | 1.1 | 0.7601 | 580808 | 0.94344464 | CS |
12 | 0.11751 | 15.5704253346 | 0.7547 | 1.1 | 0.6354 | 563463 | 0.8292305 | CS |
26 | -0.31779 | -26.7050420168 | 1.19 | 1.27 | 0.6354 | 685683 | 0.89783743 | CS |
52 | -1.54779 | -63.9582644628 | 2.42 | 3.1399 | 0.6354 | 486677 | 1.1937658 | CS |
156 | -11.97279 | -93.209731413 | 12.845 | 13.525 | 0.6354 | 252123 | 2.5338247 | CS |
260 | -41.14779 | -97.9242979534 | 42.02 | 63.62 | 0.6354 | 233147 | 6.46406655 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions